Latest Market Expansion News

Infomedia Ltd has agreed to acquire a 50% stake in European AI startup Intellegam GmbH for €6.1 million, marking a strategic leap to integrate cutting-edge generative AI into its automotive data solutions. The deal sets a clear path to full ownership within five years, underpinning Infomedia’s innovation-driven growth agenda.

AVITA Medical reported a robust 30% increase in Q4 2024 commercial revenue alongside key FDA clearances, setting the stage for ambitious growth in 2025.

Cochlear Limited posted a 6% increase in HY25 sales revenue driven by strong implant sales but anticipates FY25 profits at the lower end of guidance due to declining services revenue and rising cloud investments.

Hancock & Gore Limited (ASX: HNG) showcased a transformative year at its 121st AGM, spotlighting a strategic merger with Schoolblazer that creates a leading global uniforms platform and signals a new phase of growth and portfolio simplification.

Prophecy International Holdings has posted a record half-year revenue of $11.6 million for H1 FY25, driven by strong demand for its AI-enabled cybersecurity and data integration products. The company’s transition to subscription models and expansion into new global markets underpin a positive outlook.

Pro Medicus Limited has delivered a record interim profit of $51.7 million, boosted by major North American contract wins and strong margin expansion.

Pro Medicus Limited delivered a robust half-year performance ending December 2024, with after-tax profits soaring 42.7% to $51.74 million and revenues climbing 31.1% to $97.2 million, driven by significant contract wins in North America and sustained growth in Australia.

Temple & Webster Group Ltd delivered a robust half-year performance with revenues climbing 24% to $313.7 million and profit after tax more than doubling to $9 million, underpinned by strategic growth initiatives and operational efficiencies.

RLF AgTech has completed a $2.4 million capital raise through an Entitlement Issue and Shortfall Placement, positioning the company for growth in Australia’s agricultural sector.

Memphasys has completed the final patient visit in its Felix™ clinical trial, with data lock expected within two weeks and preliminary results slated for early March 2025. This milestone paves the way for CE Mark submission and imminent commercialisation in Europe.

Cann Group Limited has negotiated an extension of its NAB loan maturity and deferred upcoming interest payments, providing crucial breathing room for its capital projects and working capital needs.

Breville Group Limited delivered a robust first half for FY25, posting double-digit revenue growth and a significant rise in net profit, underpinned by strong consumer demand and proactive inventory management to counter tariff risks.